ATE205850T1 - Behandlung der toxischen wirkung von chemotherapeutischen und antiviralen wirkstoffen mit acylierten pyrimidinnukleosiden - Google Patents

Behandlung der toxischen wirkung von chemotherapeutischen und antiviralen wirkstoffen mit acylierten pyrimidinnukleosiden

Info

Publication number: ATE205850T1
Authority: AT; Austria
Prior art keywords: treatment; chemotherapeutic; antiviral agents; pyrimidine nucleosides; toxic effects
Prior art date: 1991-07-05

Application number

AT92914215T

Other languages

English (en)

Inventor

Borstel Reid W Von

Michael K Bamat

Original Assignee

Pro Neuron Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-05

Filing date

1992-06-25

Publication date

2001-10-15

1992-06-25 Application filed by Pro Neuron Inc filed Critical Pro Neuron Inc

2001-10-15 Application granted granted Critical

2001-10-15 Publication of ATE205850T1 publication Critical patent/ATE205850T1/de

Links

239000002246 antineoplastic agent Substances 0.000 title abstract 2
239000003443 antiviral agent Substances 0.000 title abstract 2
239000002718 pyrimidine nucleoside Substances 0.000 title abstract 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
230000000973 chemotherapeutic effect Effects 0.000 title 1
231100000331 toxic Toxicity 0.000 title 1
230000002588 toxic effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
241001465754 Metazoa Species 0.000 abstract 1
230000000118 anti-neoplastic effect Effects 0.000 abstract 1
230000000840 anti-viral effect Effects 0.000 abstract 1
238000002512 chemotherapy Methods 0.000 abstract 1
229940127089 cytotoxic agent Drugs 0.000 abstract 1
210000000777 hematopoietic system Anatomy 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003230 pyrimidines Chemical class 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Tropical Medicine & Parasitology (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

AT92914215T 1991-07-05 1992-06-25 Behandlung der toxischen wirkung von chemotherapeutischen und antiviralen wirkstoffen mit acylierten pyrimidinnukleosiden ATE205850T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72434091A	1991-07-05	1991-07-05
PCT/US1992/005324 WO1993001202A1 (en)	1991-07-05	1992-06-25	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

Publications (1)

Publication Number	Publication Date
ATE205850T1 true ATE205850T1 (de)	2001-10-15

Family

ID=24910042

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92914215T ATE205850T1 (de)	1991-07-05	1992-06-25	Behandlung der toxischen wirkung von chemotherapeutischen und antiviralen wirkstoffen mit acylierten pyrimidinnukleosiden

Country Status (12)

Country	Link
EP (1)	EP0594667B1 (de)
JP (1)	JP2584947B2 (de)
KR (1)	KR100256144B1 (de)
AT (1)	ATE205850T1 (de)
AU (1)	AU667676B2 (de)
CA (2)	CA2504078C (de)
DE (1)	DE69232070T2 (de)
DK (1)	DK0594667T3 (de)
ES (1)	ES2160579T3 (de)
GR (1)	GR3036749T3 (de)
WO (1)	WO1993001202A1 (de)
ZA (1)	ZA924975B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5968914A (en) *	1987-10-28	1999-10-19	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US7173017B1 (en)	1987-10-28	2007-02-06	Wellstat Therapeutics Corporation	Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US6329350B1 (en)	1987-10-28	2001-12-11	Pro-Neuron, Inc.	Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
CN101066276A (zh)	1994-07-01	2007-11-07	威尔斯塔特医疗公司	用于治疗全身性炎症和炎性肝炎的嘧啶核苷酸前体
CA2189097A1 (en) *	1995-11-15	1997-05-16	Pin-Fang Lin	Composition and method of treating retroviral infection
US5719132A (en) *	1996-06-27	1998-02-17	Bristol-Myers Squibb Company	Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
US6875751B2 (en)	2000-06-15	2005-04-05	Idenix Pharmaceuticals, Inc.	3′-prodrugs of 2′-deoxy-β-L-nucleosides
DE10110355A1 (de) *	2001-03-03	2002-09-12	Ulrich Walker	Bekämpfung von Nebenwirkungen
US6905669B2 (en)	2001-04-24	2005-06-14	Supergen, Inc.	Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6982253B2 (en)	2002-06-05	2006-01-03	Supergen, Inc.	Liquid formulation of decitabine and use of the same
US7250416B2 (en)	2005-03-11	2007-07-31	Supergen, Inc.	Azacytosine analogs and derivatives
US7700567B2 (en)	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2009114325A2 (en)	2008-03-03	2009-09-17	Tosk, Incorporated	Methotrexate adjuvants to reduce toxicity and methods for using the same
HUE042327T2 (hu)	2011-08-30	2019-06-28	Astex Pharmaceuticals Inc	Decitabin-származék készítmények
EP2767543B1 (de) *	2011-10-14	2017-08-30	Aktsionernoe Obshcestvo "Proizvodstvenno-Kommercheskaya Assotsiatsiya AZT"	Salze aus carbamoylphosphonsäureester als selektive inhibitoren der produktion des humanen immundefizienzvirus hiv-1
WO2017004538A1 (en)	2015-07-02	2017-01-05	Otsuka Pharmaceutical Co., Ltd.	Lyophilized pharmaceutical compositions
US10874683B2 (en)	2016-03-10	2020-12-29	Emory University	N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2018089928A1 (en) *	2016-11-11	2018-05-17	Whitehead Institute For Biomedical Research	Human plasma-like medium
BR112020002280A2 (pt)	2017-08-03	2020-07-28	Otsuka Pharmaceutical Co., Ltd.	composto farmacológico e métodos purificação do mesmo
EP3836942A4 (de)	2018-08-14	2022-05-18	Tosk, Inc.	Verfahren und zusammensetzungen zur verminderung der strahlungsinduzierten toxizität
EP3836941A4 (de) *	2018-08-14	2022-05-18	Tosk, Inc.	Verfahren und zusammensetzungen zur behandlung von mukositis
WO2020036975A1 (en) *	2018-08-14	2020-02-20	Tosk, Inc.	Methods and compositions for reducing fluorouracil induced toxicity
US11446303B2 (en)	2019-06-21	2022-09-20	Tosk, Inc.	Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
WO2022010778A1 (en)	2020-07-07	2022-01-13	Tosk, Inc.	Uridine phosphorylase inhibitors to treat or prevent pulmonary disease
US20260137674A1 (en)	2024-10-23	2026-05-21	Incyte Corporation	Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3100478A1 (de) *	1981-01-09	1982-08-12	Dr. Thilo & Co GmbH, 8021 Sauerlach	5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
EP0151189B1 (de) *	1983-07-20	1990-01-31	Teijin Limited	Antineoplastisches mittel
EP0339075B1 (de) *	1987-10-28	1993-08-18	Pro-Neuron, Inc.	Acylatiertes uridin und cytidin und deren verwendungen
EP0355131B1 (de) *	1987-10-28	1996-09-04	Pro-Neuron, Inc.	Acyl deoxyribonukleosid-derivate und deren verwendungen
AU7623991A (en) *	1990-05-17	1991-11-21	Syntex (U.S.A.) Inc.	Antiviral agents
CA2444071C (en) *	1991-02-08	2008-10-07	Wellstat Therapeutics Corporation	Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis

1992
- 1992-06-25 AT AT92914215T patent/ATE205850T1/de not_active IP Right Cessation
- 1992-06-25 DE DE69232070T patent/DE69232070T2/de not_active Expired - Lifetime
- 1992-06-25 KR KR1019940700025A patent/KR100256144B1/ko not_active Expired - Lifetime
- 1992-06-25 DK DK92914215T patent/DK0594667T3/da active
- 1992-06-25 AU AU22544/92A patent/AU667676B2/en not_active Ceased
- 1992-06-25 CA CA002504078A patent/CA2504078C/en not_active Expired - Lifetime
- 1992-06-25 ES ES92914215T patent/ES2160579T3/es not_active Expired - Lifetime
- 1992-06-25 JP JP5502244A patent/JP2584947B2/ja not_active Expired - Lifetime
- 1992-06-25 EP EP92914215A patent/EP0594667B1/de not_active Expired - Lifetime
- 1992-06-25 WO PCT/US1992/005324 patent/WO1993001202A1/en not_active Ceased
- 1992-06-25 CA CA002111571A patent/CA2111571C/en not_active Expired - Lifetime
- 1992-07-03 ZA ZA924975A patent/ZA924975B/xx unknown
2001
- 2001-09-27 GR GR20010401606T patent/GR3036749T3/el unknown

Also Published As

Publication number	Publication date
AU667676B2 (en)	1996-04-04
ZA924975B (en)	1993-04-28
EP0594667B1 (de)	2001-09-19
JPH06508846A (ja)	1994-10-06
HK1003424A1 (en)	1998-10-30
CA2504078C (en)	2007-08-28
GR3036749T3 (en)	2001-12-31
KR100256144B1 (ko)	2000-05-15
EP0594667A1 (de)	1994-05-04
DE69232070D1 (de)	2001-10-25
WO1993001202A1 (en)	1993-01-21
DE69232070T2 (de)	2002-06-06
CA2111571C (en)	2005-08-23
AU2254492A (en)	1993-02-11
JP2584947B2 (ja)	1997-02-26
EP0594667A4 (en)	1996-01-10
CA2504078A1 (en)	1993-01-21
ES2160579T3 (es)	2001-11-16
DK0594667T3 (da)	2001-11-12
CA2111571A1 (en)	1993-01-21

Legal Events

Date	Code	Title
2002-02-15	UEP	Publication of translation of european patent specification
2003-03-15	EEFA	Change of the company name
2012-03-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69232070D1 (de)	2001-10-25	Behandlung der toxischen wirkung von chemotherapeutischen und antiviralen wirkstoffen mit acylierten pyrimidinnukleosiden
ES2138969T3 (es)	2000-02-01	Combinacion de nucleosidos antivirales.
DK0526537T3 (da)	1995-10-02	5-Benzylbarbituratderivater
YU176191A (sh)	1994-01-20	Derivati hinazolina za pojačavanje antitumorne aktivnosti
DK0604910T3 (da)	2000-07-31	Phosphonooxymethylethere af taxanderivater
ITMI921203A0 (it)	1992-05-19	Derivati di s-triazina come agenti fotostabilizzanti
DE69430611D1 (de)	2002-06-20	Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel
DE69908819D1 (de)	2003-07-17	Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
FI933568A0 (fi)	1993-08-12	9-((substituerad glycyl)amido)-6-demetyl-6-deoxitetracykliner
ATE267164T1 (de)	2004-06-15	9-(substituiertes glycyl)amido-6-(substituiert)-5-hydroxy-6-deoxy etracycline
FR2681862B1 (fr)	1993-11-12	Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
MX9303711A (es)	1994-05-31	Nucleosidos de pirimida sustituida que tienen actividad anti-tumoral y anti-viral y composicion farmaceutica que los contiene.
DE69119074D1 (de)	1996-05-30	Kovalente-ther lipidnukleosid-konjugate
NZ229453A (en)	1991-08-27	A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
DK0489877T3 (da)	1996-02-05	Antiatherosklerotiske og antithrombotiske 2-amino-6-phenyl-4H-pyran-4-oner
EP0453247A3 (de)	1991-11-06	Antivirale Verbindungen
MX9709749A (es)	1998-03-31	Metodo para reducir la toxicidad de agentes quimioterapeuticos y antivirales con nucleosidos de pirimidina acilados.
KR960703127A (ko)	1996-06-19	구충제로서 유용한 14-치환된 마르크포틴 및 유도체(14-substituted marcfortin and derivatives useful as antiparasitic agents)
ATE47863T1 (de)	1989-11-15	Makrolide derivate.
MX9304283A (es)	1994-02-28	Derivados de tiadiazinona, procedimiento para su preparacion y preparacion farmaceutica que los con tienen.
ES2073915T3 (es)	1995-08-16	6,9-bis(amino sustituido)benzo g)ftalazin-5,10-diona como agentes antitumorales.
MX9102245A (es)	1992-07-08	Combinaciones de compuestos vainilloides y compuestos antivirales de nucleosido para el tratamiento de infecciones de herpes
MX9203358A (es)	1992-07-01	Derivados de bencimidazol y composicines farmaceuticas que los contienen.
TH16581A (th)	1995-09-27	สารเสริมกำลังภูมิคุ้มกันและให้การป้องกันและกรรม?วิธีของการเตรียมสารนี้
FR2669641B1 (fr)	1995-08-04	Agents porogenes consistant en tetrazoles et leurs derives.